Amyotrophic Lateral Sclerosis
Conditions
Keywords
Amyotrophic lateral sclerosis, Vitamin D, Blood Levels
Brief summary
The main objective of this study is to investigate the correlation between the rate of motor decline and blood levels of Vitamin D total. Secondary objectives are to investigate the relationship between blood levels of vitamin D and total disease duration of ALS, forced vital capacity, weight loss, age of onset and the start site of ALS.
Detailed description
Amyotrophic lateral sclerosis is one of the most serious neurodegenerative disease, leading to death in 3 years by progressive paralysis of 4 limbs, speech, swallowing and breathing, and due to a progressive death of central and peripheral neurons. The cause of the disease is unknown, but an immunologically factor is more precisely suspected in ALS. Since 2008, the work of Immunology have shown that vitamin D was a major regulator of immunity. It regulates particularly the function of dendritic cells and regulates the immune response in macrophages. A vitamin D deficiency will induce activation of microglia. In neurology, vitamin D deficiency is associated with a greater impairment in neuronal function. This deficit is associated with a faster alteration of the microvasculature, alteration known to increase neuronal suffering and to enhance the neurodegenerative processes. The investigators postulate that ALS patients have a more severe prognosis if their vitamin D levels at the time of diagnosis is lower. The main objective of this study is to investigate the correlation between the rate of motor decline and blood levels of Vitamin D total. Secondary objectives are to investigate the relationship between blood levels of vitamin D and total disease duration of ALS, forced vital capacity, weight loss, age of onset and the start site of ALS.
Interventions
PROCEDUREBlood test
Blood test
Sponsors
University Hospital, Montpellier
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
* Subject with possible, probable or definite Amyotrophic Lateral Sclerosis (ALS). * ALS operating for less than three years at dosage of vitamin D time. * Subject monitored in the center ALS of Montpellier for 6 months. * Subject agreeing to give his consent in writing or orally if the patient SLA is unable to write
Exclusion criteria
* Subject has received a Vitamine D treatment in the six months preceding the inclusion * Subject with a clinical condition on the inclusion day that makes it highly probable death in the year (quadriplegic patient, subject ventilated for respiratory failure in ALS, major malnutrition) or with ALSFRS-R score \<20. * Pregnant or breastfeeding women * Subject not covered by a social security scheme. * Subject under guardianship * Adult protected by the law
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vitamin D blood level | Day 1 | The vitamine D blood level will be assessed the day of the inclusion of the patient. |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORWilliam Camu, PU PH
UH Montpellier
Outcome results
None listed